학술논문
Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate
Document Type
Article
Author
Source
In: Journal of Prevention of Alzheimer's Disease . (Journal of Prevention of Alzheimer's Disease, October 2022, 9(4):780-790)
Subject
Language
English
ISSN
24260266
22745807
22745807